Advantage Alpha Capital Partners LP Cuts Stock Position in ANI Pharmaceuticals, Inc. $ANIP

Advantage Alpha Capital Partners LP cut its position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 22.0% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 7,952 shares of the specialty pharmaceutical company’s stock after selling 2,247 shares during the period. Advantage Alpha Capital Partners LP’s holdings in ANI Pharmaceuticals were worth $519,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in ANIP. Global Alpha Capital Management Ltd. grew its holdings in shares of ANI Pharmaceuticals by 17.2% in the second quarter. Global Alpha Capital Management Ltd. now owns 862,090 shares of the specialty pharmaceutical company’s stock worth $56,251,000 after acquiring an additional 126,500 shares during the period. Aberdeen Group plc lifted its stake in shares of ANI Pharmaceuticals by 76.1% in the 1st quarter. Aberdeen Group plc now owns 419,099 shares of the specialty pharmaceutical company’s stock worth $28,059,000 after purchasing an additional 181,134 shares during the period. Charles Schwab Investment Management Inc. boosted its holdings in shares of ANI Pharmaceuticals by 0.9% in the first quarter. Charles Schwab Investment Management Inc. now owns 238,377 shares of the specialty pharmaceutical company’s stock worth $15,959,000 after buying an additional 2,220 shares during the last quarter. Nomura Holdings Inc. grew its position in ANI Pharmaceuticals by 1.5% during the first quarter. Nomura Holdings Inc. now owns 217,176 shares of the specialty pharmaceutical company’s stock valued at $14,540,000 after buying an additional 3,297 shares during the period. Finally, Northern Trust Corp increased its holdings in ANI Pharmaceuticals by 6.1% during the first quarter. Northern Trust Corp now owns 216,862 shares of the specialty pharmaceutical company’s stock valued at $14,519,000 after buying an additional 12,517 shares during the last quarter. Hedge funds and other institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Stock Up 1.4%

Shares of ANI Pharmaceuticals stock opened at $84.36 on Friday. The company has a quick ratio of 1.96, a current ratio of 2.54 and a debt-to-equity ratio of 1.39. The company has a market cap of $1.90 billion, a P/E ratio of -109.56 and a beta of 0.54. The firm’s 50 day moving average price is $89.92 and its 200-day moving average price is $78.81. ANI Pharmaceuticals, Inc. has a 52-week low of $52.50 and a 52-week high of $99.50.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings results on Friday, November 7th. The specialty pharmaceutical company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $1.74 by $0.30. ANI Pharmaceuticals had a positive return on equity of 25.03% and a negative net margin of 1.37%.The company had revenue of $227.81 million during the quarter, compared to analysts’ expectations of $211.92 million. During the same period last year, the business earned $1.34 earnings per share. ANI Pharmaceuticals’s quarterly revenue was up 53.6% on a year-over-year basis. ANI Pharmaceuticals has set its FY 2025 guidance at 7.370-7.640 EPS. On average, sell-side analysts predict that ANI Pharmaceuticals, Inc. will post 3.86 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on the company. Guggenheim lifted their price objective on ANI Pharmaceuticals from $114.00 to $115.00 and gave the company a “buy” rating in a research report on Monday, November 10th. Weiss Ratings restated a “buy (b-)” rating on shares of ANI Pharmaceuticals in a research note on Monday. Zacks Research upgraded ANI Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 21st. JPMorgan Chase & Co. upped their price objective on ANI Pharmaceuticals from $95.00 to $115.00 and gave the stock an “overweight” rating in a research note on Wednesday, September 24th. Finally, Piper Sandler reissued an “overweight” rating and set a $94.00 target price on shares of ANI Pharmaceuticals in a research note on Friday, August 8th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, ANI Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $99.29.

Insiders Place Their Bets

In other news, Director Patrick D. Walsh sold 8,643 shares of ANI Pharmaceuticals stock in a transaction on Thursday, November 13th. The shares were sold at an average price of $86.88, for a total transaction of $750,903.84. Following the completion of the sale, the director directly owned 61,405 shares of the company’s stock, valued at approximately $5,334,866.40. The trade was a 12.34% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Chad Gassert sold 14,642 shares of ANI Pharmaceuticals stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $89.07, for a total value of $1,304,162.94. Following the completion of the sale, the senior vice president directly owned 158,584 shares in the company, valued at $14,125,076.88. This represents a 8.45% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders sold 32,871 shares of company stock worth $2,963,993. 11.10% of the stock is currently owned by insiders.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.